| Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers D Rangachari, N Yamaguchi, PA VanderLaan, E Folch, A Mahadevan, ... Lung cancer 88 (1), 108-111, 2015 | 496 | 2015 |
| Combination olaparib and temozolomide in relapsed small-cell lung cancer AF Farago, BY Yeap, M Stanzione, YP Hung, RS Heist, JP Marcoux, ... Cancer discovery 9 (10), 1372-1387, 2019 | 204 | 2019 |
| Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes PA VanderLaan, D Rangachari, SM Mockus, V Spotlow, HV Reddi, ... Lung cancer 106, 17-21, 2017 | 180 | 2017 |
| Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches M Shea, DB Costa, D Rangachari Therapeutic advances in respiratory disease 10 (2), 113-129, 2016 | 169 | 2016 |
| Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival GJ Arnaoutakis, D Rangachari, DA Laheru, CA Iacobuzio-Donahue, ... Journal of Gastrointestinal Surgery 15 (9), 1611-1617, 2011 | 165 | 2011 |
| Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1≥ 50% expression in lung adenocarcinoma D Rangachari, PA VanderLaan, M Shea, X Le, MS Huberman, ... Journal of thoracic oncology 12 (5), 878-883, 2017 | 148 | 2017 |
| Association of performance status with survival in patients with advanced non–small cell lung cancer treated with pembrolizumab monotherapy K Sehgal, RR Gill, P Widick, P Bindal, DC McDonald, M Shea, ... JAMA network open 4 (2), e2037120-e2037120, 2021 | 118 | 2021 |
| Safety and efficacy of PD-1 inhibitors among HIV-positive patients with non–small cell lung cancer L Ostios-Garcia, J Faig, GC Leonardi, AE Adeni, SJ Subegdjo, CA Lydon, ... Journal of Thoracic Oncology 13 (7), 1037-1042, 2018 | 95 | 2018 |
| Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation SE Jorge, S Schulman, JA Freed, PA VanderLaan, D Rangachari, ... Lung cancer 90 (3), 369-374, 2015 | 91 | 2015 |
| Integrating palliative care in oncology: the oncologist as a primary palliative care provider D Rangachari, TJ Smith The Cancer Journal 19 (5), 373-378, 2013 | 85 | 2013 |
| EGFR-mutated lung cancers resistant to osimertinib through EGFR C797S respond to first-generation reversible EGFR inhibitors but eventually acquire EGFR T790M/C797S in … D Rangachari, C To, JE Shpilsky, PA VanderLaan, SS Kobayashi, ... Journal of Thoracic Oncology 14 (11), 1995-2002, 2019 | 81 | 2019 |
| When should tumor genomic profiling prompt consideration of germline testing? K DeLeonardis, L Hogan, SA Cannistra, D Rangachari, N Tung Journal of oncology practice 15 (9), 465-473, 2019 | 79 | 2019 |
| EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors PENS Vasconcelos, C Gergis, H Viray, A Varkaris, M Fujii, D Rangachari, ... JTO clinical and research reports 1 (3), 100051, 2020 | 72 | 2020 |
| PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non–small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell … VF Torous, D Rangachari, BP Gallant, M Shea, DB Costa, ... Journal of the American Society of Cytopathology 7 (3), 133-141, 2018 | 71 | 2018 |
| Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors RK Leaf, C Ferreri, D Rangachari, J Mier, W Witteles, G Ansstas, ... American journal of hematology 94 (5), 563-574, 2019 | 70 | 2019 |
| Tumor biomarker testing in non-small-cell lung cancer: a decade of change PA VanderLaan, D Rangachari, A Majid, MS Parikh, SP Gangadharan, ... Lung Cancer 116, 90-95, 2018 | 63 | 2018 |
| EGFR testing in advanced non–small-cell lung cancer, a mini-review Y Sheikine, D Rangachari, DC McDonald, MS Huberman, ES Folch, ... Clinical lung cancer 17 (6), 483-492, 2016 | 61 | 2016 |
| EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas SE Jorge, AR Lucena-Araujo, H Yasuda, Z Piotrowska, GR Oxnard, ... Clinical Cancer Research 24 (24), 6548-6555, 2018 | 59 | 2018 |
| Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors K Sehgal, R Patell, D Rangachari, DB Costa Translational cancer research 7 (Suppl 7), S779, 2018 | 59 | 2018 |
| Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection A Pertejo-Fernandez, B Ricciuti, SP Hammond, FM Marty, G Recondo, ... Lung Cancer 145, 181-185, 2020 | 44 | 2020 |
